Health Care/Hospital

Achieva Medical Entered into an Exclusive Distribution Agreement with NowYon Medical

SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its wholly-owned subsidiary, Achieva Medical Limited ("Achieva Medical"), entered ...

2024-08-28 16:40 1203

Laifen to Launch World's First Titanium Electric Toothbrush at IFA 2024

BERLIN, Aug. 28, 2024 /PRNewswire/ -- Laifen , a pioneering lifestyle-tech brand, is set to break new ground in oral care with the launch of the Laifen Wave Electric Toothbrush Titanium atIFA Berlin 2024 . This marks Laifen's thir...

2024-08-28 14:00 1317

Yunovia Announces IND Approval by the MFDS to Initiate Phase 1 MAD Study for the Small Molecule GLP-1 Agonist

SEOUL, South Korea, Aug. 27, 2024 /PRNewswire/ -- Yunovia, a drug R&D subsidiary of Ildong Pharmaceutical Group, announced on the 26th that the Ministry of Food and Drug Safety (MFDS) of Korea has cleared the IND application of Phase 1 Multiple Ascending Dose (MAD) study for ID110521156, an oral...

2024-08-28 10:43 1462

Shilpa Medicare Makes History: First Indian Company Completes Phase 1 Trial for Recombinant Human Albumin (rHA) 20%

RAICHUR, India, Aug. 28, 2024 /PRNewswire/ -- In a major breakthrough, Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) proudly announces the successful completion of its Phase 1 clinical trial for its flagship product,sRbumin® - recombinant human albumin® 20% (rH...

2024-08-28 09:00 1729

Jenscare, with innovative TTVR, releases 2024H1 interim results

BEIJING, Aug. 28, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, released interim results for 2024H1 endedJune 30, 2024...

2024-08-28 09:00 2061

Everest Medicines Announces Interim Results for First Half of 2024

SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2024 a...

2024-08-28 08:00 2191

Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent

MELBOURNE, Australia, Aug. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) tothe United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET)...

2024-08-28 07:53 1586

Unique International Collaboration Brings Breakthrough Oral Cholera Vaccine to Market

Singapore-based Hilleman Laboratories, along with Bharat Biotech, confirm launch of new cholera vaccine, HILLCHOL® Success provides "template for the internationalization of future vaccine and biologics development fromSingapore" – Dr. Raman Rao, CEO, Hilleman Laboratories Hilleman Laboratories ...

2024-08-28 00:00 2136

Boan Biotech Announces 2024 Half Year Results: Revenue Grows by 39%, Net Profit Increases by RMB 180 Million

YANTAI, China, Aug. 27, 2024 /PRNewswire/ -- Boan Biotech (6955.HK) today announced its 2024 half-year results and latest developments. During the reporting period, the company's total revenue was RMB 363 million, up 39% year-over-year. In this, the revenue from product sales wasRMB 332 million,...

2024-08-27 22:55 2573

GenScript Subsidiary Legend Biotech Achieves Breakthrough with Cilta-cel Approval in China, Offering New Hope for Multiple Myeloma Patients

PISCATAWAY, N.J., Aug. 27, 2024 /PRNewswire/ -- Legend Biotech (NASDAQ: LEGN), a subsidiary of GenScript Biotech Corporation (hereinafter referred to as "GenScript"), a global leader in life sciences research and manufacturing services, today announced that they have received approval from the Ch...

2024-08-27 22:28 1141

Keymed Biosciences Announces Interim Results for First Half of 2024

CHENGDU, China , Aug. 27, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update.  Rapid development of our pipeline products Stapokibart (CM310) (IL-4Rα antibody) * In June 2024, the long-term e...

2024-08-27 21:10 2062

Sleep Specialists and Industry Leaders Converge at HoneyNaps Symposium

* The 1st HoneyNaps Sleep & Tech Symposium * Presentation of the 'SLEEP 2024 White Paper' and the Latest Advances in Sleep Research & Technology * Unveiling of HoneyNaps' New Brand Identity BOSTON, Aug. 27, 2024 /PRNewswire/ -- HoneyNapsUSA, Inc., an AI-driven sleep data analysis company, p...

2024-08-27 21:00 1849

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

BRENTWOOD, Tenn., Aug. 27, 2024 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax") today announced the results of a Cardiovascular Health Outcomes Analysis (HOA). The results showed there is no evidence of excess cardiovascular risk and no statistically significant difference in major adverse...

2024-08-27 20:05 2460

111, Inc. to Participate in Fireside Chat with Water Tower Research on September 5, 2024

SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that it will parti...

2024-08-27 20:00 1439

YolTech Announces Licensing Agreement with Salubris for the Development and Commercialization of YOLT-101 in Mainland China

SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, announced today that it has entered into an exclusive licensing agreement with Salubris Pharmaceuticals Co., Ltd. (stock code: 002294.SZ), a leadi...

2024-08-27 18:30 1156

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina has approv...

2024-08-27 17:00 2288

HKBU research identifies potential of phosphocholine in counteracting PM2.5 toxicity in lung diseases

HONG KONG, Aug. 27, 2024 /PRNewswire/ -- A research team led by Hong Kong Baptist University (HKBU) has discovered that phosphocholine, an important component in the body's metabolism, could counteract the adverse effects of PM2.5 toxicity on lung cells. This discovery highlights the therapeutic ...

2024-08-27 13:28 1748

FWD Group announces strong first half 2024 financial results

HONG KONG, Aug. 27, 2024 /PRNewswire/ -- FWD Group Holdings Limited ("FWD Group" or "FWD") today announced strong half year results for the six months ended30 June 2024. * Operating profit after tax of US$223 million, reflecting positive contributions from all four geographic business segmen...

2024-08-27 12:08 2164

Frost & Sullivan Awards Avance Clinical for Global Biotech CRO Excellence, Highlighting Agility, Responsiveness, Customer Value, and Proven Ability to Expedite Quality Clinical Programs

Avance Clinical streamlines its biotech clients' clinical trial operations, workflows, and data management, optimizing study efficiencies,minimizing costs, and accelerating trial timelines. SAN ANTONIO, Aug. 27, 2024 /PRNewswire/ -- Frost & Sullivan recently assessed the biotech contract researc...

2024-08-27 11:30 1300

2024 TPI Day Convenes Expert Views on Sustainability, Open Source and AI

TAIPEI, Aug. 27, 2024 /PRNewswire/ -- TPIsoftware hosts its annual forum TPI Day in collaboration with Taipei Medical Alliance and multinational open-source software company SUSE to foster insightful dialogues on industry trends: Sustainability, Open Source and Artificial Intelligence (AI). Held ...

2024-08-27 11:11 609
1 ... 43444546474849 ... 847

Week's Top Stories